Differential role of mesangial cells and podocytes in TGF-ß-induced mesangial matrix synthesis in chronic glomerular disease

Histology and Histopathology

Volumn 24, Issue 7, 2009, Pages 901-908

  Lee, Hyun Soon ^a   Song, Chi Young ^a  

^a Seoul National University   (South Korea)

Author keywords

Chronic glomerular disease; Glomerulosclerosis; Mesangial matrix; Podocytes; TGF activation

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; CHRONIC DISEASE; CYTOLOGY; EXTRACELLULAR MATRIX; GENETICS; GLOMERULUS; HUMAN; MESANGIUM; METABOLISM; PATHOLOGY; PODOCYTE; REVIEW; SCLEROSIS;

ANIMALS; CHRONIC DISEASE; EXTRACELLULAR MATRIX; GLOMERULAR MESANGIUM; HUMANS; KIDNEY GLOMERULUS; PODOCYTES; SCLEROSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 68849117435     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Abbate M., Zoja C., Morigi M., Rottoli D., Angioletti S., Tomasoni S., Zanchi C., Longaretti L., Donadelli R. and Remuzzi G. (2002). Transforming growth factor-ß1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. Am. J. Pathol. 161, 2179-2193.
2. Abdelouahed M., Ludlow A., Brunner G. and Lawler J. (2000). Activation of platelet transforming growth factor ß-1 in the absence of thrombospondin-1. J. Biol. Chem. 275, 17933-17936.
3. Abreu J.G., Ketpura N.I., Reversade B. and Robertis E.M. (2002). Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-ß. Nature Cell Biol. 4, 599-604.
4. Annes J.P., Chen Y., Munger J.S. and Rifkin D.B. (2004). Integrin avß6-mediated activation of latent TGF-ß requires the latent TGF-ßbinding protein-1. J. Cell Biol. 165, 723-734.
5. Annes J.P., Munger J.S. and Rifkin D.B. (2003). Making sense of latent TGFß activation. J. Cell Sci. 116, 217-224.
6. Barcellos-Hoff M.H. and Dix T.A. (1996). Redox-mediated activation of latent transforming growth factor-ß1. Mol. Endocrinol. 10, 1077-1083.
7. Baricos W.H., Reed J.C. and Cortez S.L. (2003). Extracellular matrix degradation by cultured mesangial cells: mediators and modulators. Exp. Biol. Med. 228, 1018-1022.
8. Benigni A., Zoja C., Corna D., Zatelli C., Conti S., Campana M., Gagliardini E., Rottoli D., Zanchi C., Abbate M., Ledbetter S. and Remuzzi G. (2003). Add-on anti-TGF-ß antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J. Am. Soc. Nephrol. 14, 1816-1824.
9. Blom I.E., van Dijk A.J., Wieten L., Duran K., Ito Y., Kleij L., deNichilo M., Rabelink T.J., Weening J.J., Aten J. and Goldschmeding R. (2001). In vitro evidence for differential involvement of CTGF, TGFß, and PDGF-BB in mesangial response to injury. Nephrol. Dial. Transplant. 16, 1139-1148.
10. Chen S., Lee J.S., Iglesias-de la Cruz M.C., Wang A., Izquierdo-Lahuerta A., Gandhi N.K., Danesh F.R., Wolf G. and Ziyadeh F.N. (2005). Angiotensin II stimulates a3(IV) collagen production in mouse podocytes via TGF-ß and VEGF signaling: implications for diabetic lomerulopathy. Nephrol. Dial. Transplant. 20, 1320-1328.
11. Chen Y., Blom I.E., Sa S., Goldschmeding R., Abraham D.J. and Leask A. (2002). CTGF expression in mesangial cells: Involvement of SMADs, MAP kinase, and PKC. Kidney Int. 62, 1149-1159.
12. Chiba Y., Ando K. and Fujita T. (2002). The protective effects of taurine against renal damage by salt loading in Dahl salt-sensitive rats. J. Hypertens. 20, 2269-2274.
13. Chow E.K., O'Connell R.M., Schilling S., Wang X-F., Fu X-Y. and Cheng G. (2005). TLR agonists regulate PDGF-B production and cell proliferation through TGF-ß/type I IFN crosstalk. EMBO J. 24, 4071-4081.
14. Coffey R.J. Jr, Kost L.J., Lyons R.M., Moses H.L. and LaRusso N.E. (1987). Hepatic processing of transforming growth factor ß in the rat. Uptake, metabolism, and biliary excretion. J. Clin. Invest. 80, 750-757.
15. Cooker L.A., Peterson D., Rambow J., Riser M.L., Riser R.E., Najmabadi F., Brigstock D. and Riser B.L. (2007). TNF-a, but not IFN-g, regulates CCN2 (CTGF), collagen type I, and proliferation in mesangial cells: possible roles in the progression of renal fibrosis. Am. J. Physiol. Renal Physiol. 293, F157-F165.
16. Crawford S.E., Stellmach V., Murphy-Ullrich J.E., Ribeiro S.M., Lawler J., Hynes R.O., Boivin G.P. and Bouck N. (1998). Thrombospondin-1 is a major activator of TGF-ß1 in vivo. Cell 93, 1159-1170.
17. Daniel C., Schaub K., Amann K., Lawler J. and Hugo C. (2007). Thrombospondin-1 is an endogenous activator of TGF-ß in experimental diabetic nephropathy in vivo. Diabetes 56, 2982-2989.
18. Daniel C., Takabatake Y., Mizui M., Isaka Y., Kawashi H., Rupprecht H., Imai E. and Hugo C. (2003). Antisense oligonucleotides against thrombospondin-1 inhibit activation of TGF-ß in fibrotic renal disease in the rat in vivo. Am. J. Pathol. 163, 1185-1192.
19. Deen W.M., Lazzara M.J. and Myers B.D. (2001). Structural determinants of glomerular permeability. Am. J. Physiol. Renal Physiol. 281, F579-F596.
20. Durvasula R.V., Petermann A.T., Hiromura K., Blonski M., Pippin J., Mundel P., Pichler R., Griffin S., Couser W.G. and Shankland S.J. (2004). Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int. 65, 30-39.
21. Edgtton K.L., Gow R.M., Kelly D.J., Carmeliet P. and Kitching A.R. (2004). Plasmin is not protective in experimental renal interstitial fibrosis. Kidney Int. 66, 68-76.
22. Flyvbjerg A., Dagnaes-Hansen F., De Vriese A.S., Schrijvers B.F., Tilton R.G. and Rasch R. (2002). Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51, 3090-3094.
23. George S.J., Johnson J.L., Smith M.A., Angelini G.D. and Jackson C.L. (2005). Transforming growth factor-ß is activated by plasmin and inhibits smooth muscle cell death in human saphenous vein. J. Vasc. Res. 42, 247-254.
24. Gianella A., Nobili E., Abbate M., Zoja C., Gelosa P., Mussoni L., Bellosta S., Canavesi M., Rottoli D., Guerrini U., Brioschi M., Banfi C., Tremoli E., Remuzzi G. and Sironi L. (2007). Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. Am. J. Pathol. 170, 1165-1177.
25. Gore-Hyer E., Shegogue D., Markiewicz M., Lo S., Hazen-Martin D., Greene E.L., Grotendorst G. and Trojanowska M. (2002). TGF-ß and CTGF have overlapping and distinct fibrogenic effects on human renal cells. Am. J. Physiol. Renal Physiol. 283, F707-F716.
26. Grainger D.J. and Frow E.K. (2000). Thrombospondin 1 does not activate transforming growth factor-ß 1 in a chemically defined system or in smooth muscle-cell cultures. Biochem. J. 350, 291-298.
27. Hartner A., Hilgers K.F., Bitzer M., Veelken R. and Schöcklmann H.O. (2003). Dynamic expression patterns of transforming growth factorß(2) and transforming growth factor-ß receptors in experimental glomerulonephritis. J. Mol. Med. 81, 32-42.
28. Hashimoto G., Inoki I., Fujii Y., Aoki T., Ikeda E. and Okada Y. (2002). Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J. Biol. Chem. 277, 36288-36295.
29. Hill C., Flyvbjerg A., Gronbaek H., Petrik H., Hill D.J., Thomas C.R., Sheppard M.C. and Logan A. (2000). The renal expression of transforming growth factor-ß isoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinology 141, 1196-1208.
30. Hugo C., Shankland S.J., Pichler R.H., Couser W.G. and Johnson R.J. (1998). Thrombospondin-1 precedes and predicts the development of tubulointerstitial fibrosis in glomerular disease in the rat. Kidney Int. 53, 302-311.
31. Hyytiäinen M., Penttinen C. and Keski-Oja J. (2004). Latent TGF-ß binding proteins: extracellular matrix association and roles in TGF-ß activation. Crit. Rev. Clin. Lab. Sci. 41, 233-264.
32. Iglesias-de la Cruz M.C., Ziyadeh F.N., Isono M., Kouahou M., Han D.C., Kalluri R., Mundel P. and Chen S. (2002). Effects of high glucose and TGF-ß1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int. 62, 901-913.
33. Ito Y., Aten J., Bende R.J., Oemar B.S., Rabelink T.J., Weening J.J. and Goldschmeding R. (1998). Expression of connective tissue growth factor in human renal fibrosis. Kidney Int. 53, 853-861.
34. Ito Y., Goldschmeding R., Bende R.J., Claessen N., Chand M.A., Kleij L., Rabelink T.J., Weening J.J. and Aten J. (2001). Kinectics of connective tissue growth factor expression during experimental proliferative glomerulonephritis. J. Am. Soc. Nephrol. 12, 472-484.
35. Jobling M.F., Mott J.D., Finnegan M.T., Jurukovski V., Erickson A.C., Walian P.J., Taylor S.E., Ledbetter S., Lawrence C.M., Rifkin D.B. and Barcellos-Hoff M.H. (2006). Isoform-specific activation of latent transforming growth factor-ß (LTGF-ß) by reactive oxygen species. Radiat. Res. 166, 839-848.
36. Kanemoto K., Usui J., Tomari S., Yokoi H., Mukoyama M., Aten J., Weening J.J. and Nagata M. (2003). Connective tissue growth factor participates in scar formation of crescentic glomerulonephritis. Lab. Invest. 83, 1615-1625.
37. Katavetin P. and Katavetin P. (2008). VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 359, 205-206.
38. Kim H.W., Moon K.C., Park S.Y., Hong H.K. and Lee H.S. (2002). Differential expression of platelet-derived growth factor and transforming growth factor ß in relation to progression of IgA nephropathy. Nephrology 7, S131-S139.
39. Kim J.H., Kim B.K., Moon K.C., Hong H.K. and Lee H.S. (2003). Activation of the TGF-ß/Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int. 64, 1715-1721.
40. Koli K., Myllärniemi M., Keski-Oja J. and Kinnula V.L. (2008). Transforming growth factor-ß activation in the lung: focus on fibrosis and reactive oxygen species. Antioxid. Redox. Signal 10, 333-342
41. Koli K., Saharinen J., Hyytiäinen M., Penttinen C. and Keski-Oja J. (2001). Latency, activation, and binding proteins of TGF-ß. Microsc. Res. Tech. 52, 354-362.
42. Kopp J.B., Factor V.M., Mozes M., Nagy P., Sanderson N., Boettinger E.P., Klotman P.E. and Thorgeirsson S.S. (1996). Transgenic mice with increased plasma levels of TGF-ß1 develop progressive renal disease. Lab. Invest. 74, 991-1003.
43. Lawrence D.A. (2001). Latent TGF-ß: An overview. Mol. Cell Biochem. 219,163-170.
44. Lee H.S., Park S.Y., Moon K.C., Hong H.K., Song C.Y. and Hong S.Y. (2001). mRNA expression of urokinase and plasminogen activator inhibitor-1 in human crescentic glomerulonephritis. Histopathology 39, 203-209.
45. Lee H.S. and Song C.Y. (2009). Oxidized low-density lipoprotein and oxidative stress in the development of glomerulosclerosis. Am. J. Nephrol. 29, 62-70.
46. Liu N., Makino T., Nogaki F., Kusano H., Suyama K., Muso E., Honda G., Kita T. and Ono T. (2004). Coagulation in the mesangial area promotes ECM accumulation through factor V expression in MsPGN in rats. Am. J. Physiol. Renal Physiol. 287, F612-F620.
47. Lyons R., Gentry L.E., Purchio A.F. and Moses H.L. (1990). Mechanism of activation of latent recombinant transforming growth factor-ß1 by plasmin. J. Cell Biol. 110, 1361-1367.
48. Matsusaka T., Xin J., Niwa S., Kobayashi K., Akatsuka A., Hashizume H., Wang Q-c., Pastan I., Fogo A.B. and Ichikawa I. (2005). Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J. Am. Soc. Nephrol. 16, 1013-1023.
49. Mu D., Cambier S., Fjellbirkeland L., Baron J.L., Munger J.S., Kawakatsu H., Sheppard D., Broaddus V.C. and Nishimura S.L. (2002). The integrin avß8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-ß1. J. Cell Biol. 157, 493-507.
50. Mundel P., Reiser J., Zuniga-Mejia-Borja A., Pavenstädt H., Davidson G., Kriz W. and Zeller R. (1997). Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp. Cell Res. 236, 248-258.
51. Munger J.S., Huang X., Kawakatsu H., Griffiths M.J., Dalton S.L., Wu J., Pittet J.F., Kaminski N., Garat C., Matthay M.A., Rifkin D.B. and Sheppard D. (1999). The integrin avß6 binds and activates latent TGFß 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96, 319-328.
52. Nagase M., Shibata S., Yoshida S., Nagase T., Gotoda T. and Fujita T. (2006). Podocyte injury underlies the glomerulopathy of Dahl salthypertensive rats and is reversed by aldosterone blocker. Hypertension 47, 1084-1093.
53. Nakagawa H., Sasahara M., Haneda M., Koya D., Hazama F. and Kikkawa R. (2000). Immunohistochemical characterization of glomerular PDGF B-chain and PDGF ß-receptor expression in diabetic rats. Diabetes Res. Clin. Pract. 48, 87-98.
54. Nguyen T.Q., Roestenberg P., van Nieuwenhoven F.A., Bovenschen N., Li Z., Xu L., Oliver N., Aten J., Joles J.A., Vial C., Brandan E., Lyons K.M. and Goldschmeding R. (2008). CTGF inhibits BMP-7 signaling in diabetic nephropathy. J. Am. Soc. Nephrol. 19, 2098-2107.
55. Ostendorf T., Kunter U., van Roeyen C., Dooley S., Janjic N., Ruckman J., Eitner F. and Floege J. (2002). The effects of platelet-derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-ß system. J. Am. Soc. Nephrol. 13, 658-657.
56. Ostendorf T., Rong S., Boor P., Wiedemann S., Kunter U., Haubold U., van Roeven C.R., Eitner F., Kawachi H., Starling G., Alvarez E., Smithson G. and Floege J. (2006). Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. J. Am. Soc. Nephrol. 17, 1054-1062.
57. Otsuka G., Stempien-Otero A., Frutkin A.D. and Dichek D.A. (2007). Mechanisms of TGF-ß1-induced intimal growth. Plasminogenindependent activities of plasminogen activator inhibitor-1 and heterogeneous origin of intimal cells. Circ. Res. 100, 1300-1307.
58. Patek C.E., Fleming S., Miles C.G., Bellamy C.O., Ladomery M., Spraggon L., Mullins J., Hastie N.D. and Hooper M.L. (2003). Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis. Hum. Mol. Genet. 12, 2379-2394.
59. Porst M., Daniel C., Plank C., Schocklmann H.O., Reinhardt D.P. and Hartner A. (2006). Induction and coexpression of latent transforming growth factor ß-binding protein-1 and fibrillin-1 in experimental glomerulonephritis. Nephron Exp. Nephrol. 102, e99-e104.
60. Riser B.L., Denichilo M., Cortes P., Baker C., Grondin J.M., Yee J. and Narins R.G. (2000). Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J. Am. Soc. Nephrol. 11, 25-38.
61. Shibata S., Nagase M., Yoshida S., Kawachi H. and Fujita T. (2007). Podocyte as the target for aldosteone. Roles of oxidative stress and Sgk1. Hypertension 49, 355-364.
62. Stein-Oakley A.N., Maguire J.A., Dowling J., Perry G. and Thomson N.M. (1997). Altered expression of fibrogenic growth factors in IgA nephropathy and focal and segmental glomerulosclerosis. Kidney Int. 51, 195-204.
63. Sung S.H., Ziyadeh F.N., Wang A., Pyagay P.E., Kanwar Y.S. and Chen S. (2006). Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J. Am. Soc. Nephrol. 17, 3093-3104.
64. Taipale J., Koli K. and Keski-Oja J. (1992). Release of transforming growth factor-ß1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin. J. Biol. Chem. 267, 25378-25384.
65. Trevillian P., Paul H., Millar E., Hibberd A. and Agrez M.V. (2004). αvß6 integrin expression in diseased and transplanted kidneys. Kidney Int. 66, 1423-1433.
66. Wahab N.A., Schaefer L., Weston B.S., Yiannikouris O., Wright A., Babelova A., Schaefer R. and Mason R.M. (2005). Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia 48, 2650-2660.
67. Wakefield L.M., Winokur T.S., Hollands R.S., Christopherson K., Levinson A.D. and Sporn M.B. (1990). Recombinant latent transforming growth factor ß1 has a longer plasma half-life in rats than active transforming growth factor ß1, and a different tissue distribution. J. Clin. Invest. 86, 1976-1984.
68. Wang L., Kwak J.H., Kim S.I., He Y. and Choi M.E. (2004). Transforming growth factor-ß1 stimulates vascular endothelial growth factor 164 via mitogen-activated protein kinase kinase 3- p38a and p38d mitogen-activated protein kinase-dependent pathway in murine mesangial cells. J. Biol. Chem. 279, 33213-33219.
69. Wang S., de Caestecker M., Kopp J., Mitu G., LaPage J. and Hirschberg R. (2006). Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J. Am. Soc. Nephrol. 17, 2504-2512.
70. Wendt T.M., Tanji N., Guo J., Kislinger T.R., Qu W., Lu Y., Bucciarelli L.G., Rong L.L., Moser B., Markowitz G.S., Stein G., Bierhaus A., Liliensiek B., Arnold B., Nawroth P.P., Stern D.M., D'Agati V.D. and Schmidt A.M. (2003). RAGE drives the develolpment of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 162, 1123-1137.
71. Weston B.S., Wahab N.A. and Mason R.M. (2003). CTGF mediates TGF-ß-induced fibronectin matrix deposition by upregulating active a5ß1 integrin in human mesangial cells. J. Am. Soc. Nephrol. 14, 601-610.
72. Whaley-Connell A., Habibi J., Nistala R., Cooper S.A., Karuparthi P.R., Hayden M.R., Rehmer N., DeMarco V.G., Andresen B.T., Wei Y., Ferrario C. and Sowers J.R. (2008). Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension 51, 474-480.
73. Whaley-Connell A.T., Chowdhury N.A., Hayden M.R., Stump C.S., Habibi J., Wiedmeyer C.E., Gallagher P.E., Tallant E.A., Cooper S.A., Link C.D., Ferrario C. and Sowers J.R. (2006). Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am. J. Physiol. Renal Physiol. 291, F1308-F1314.
74. Wolf G., Chen S. and Ziyadeh F.N. (2005). From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 54, 1626-1634.
75. Xu J., Yao B., Fan X., Langworthy M.M., Zhang M-Z. and Harris R.C. (2007). Characterization of a putative intrarenal serotonergic system. Am. J. Physiol. Renal Physiol. 293, F1468-F1475.
76. Yamabe H., Osawa H., Kaizuka M., Tsunoda S., Shirato K-i., Tateyama F. and Okumura K. (2000). Platelet-derived growth factor, basic fibroblast growth factor, and interferon g increase type IV collagen production in human fetal mesangial cells via a transforming growth factor-ß-dependent mechanism. Nephrol. Dial. Transplant. 15, 872-876.
77. Yokoi H., Mukoyama M., Mori K., Kasahara M., Suganami T., Sawai K., Yoshioka T., Saito Y., Ogawa Y., Kuwabara T., Sugawara A. and Nakao K. (2008). Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. Kidney Int. 73, 446-455.
78. Yu L., Border W.A., Anderson I., McCourt M., Huang Y. and Noble N.A. (2004). Combining TGF-ß inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int. 66,1774-1784.
79. Yu Q. and Stamenkovic I. (2000). Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-ß and promotes tumor invasion and angiogenesis. Genes Dev. 14, 163-176.
80. Zheng S., Carlson E.C., Yang L., Kralik P.M., Huang Y. and Epstein P.N. (2008). Podocyte-specific overexpression of the antioxidant metallothionein reduces diabetic nephropathy. J. Am. Soc. Nephrol. 19, 2077-2085.
81. Ziyadeh F.N. and Wolf G. (2008). Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr. Diabetes Rev. 4, 39-45.
82. Ziyadeh F.N., Hoffman B.B., Han D.C., Iglesias-de la Cruz M.C., Hong S.W., Isono M., Chen S., McGowan T.A. and Sharma K. (2000). Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-ß antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. USA 97, 8015-8020.